

Special Issue

Immune Landscape of Renal Cell Carcinoma

Message from the Guest Editors

Immune checkpoint inhibitors (ICIs) are now firmly established as part of front-line treatment regimens for advanced disease and associated with improved response rates, durability of disease control, and overall survival. Yet, despite these important gains, clinical outcomes remain heterogenous. Primary or acquired treatment resistance is observed in most patients, with the predominant result being that metastatic disease remains largely incurable. The aim of this Special Issue is to broadly address both the advantages and disadvantages of ICIs and other immune-based therapies for advanced RCC, exploring clinical outcomes derived from the use of standard-of-care and novel emerging immunotherapy agents and combinations; translational studies including biomarker discovery, tumor antigen identification, and the investigation of mechanisms for tumor resistance and escape; and the preclinical modeling of RCC-directed immunotherapy. For this Special Issue, we welcome the submission of review papers and original research articles. *We look forward to receiving your contributions.*

Guest Editors

Dr. Scott S. Tykodi

University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA

Dr. Yuexin Xu

University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA

Deadline for manuscript submissions

30 November 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/201526

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)